The healthcare sector is havin-To The Moon - Tiger Brokers Online Investing Community - To The Moon

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

Healthcare Recovery: Can Hims Earnings Keep Pace With LLY and NVO?

Hims & Hers is set to report Q1 earnings, with focus on GLP-1 compounded semaglutide's quarterly revenue contribution and user growth, alongside the latest FDA regulatory developments on compounded drugs. Analyst sentiment is sharply divided — bulls argue HIMS has hedged GLP-1 compliance risk through product line diversification, while bears warn an outright FDA ban on compounded versions could trigger a steep revenue cliff. LLY delivered a strong earnings beat this season, surging 10% on the day. Can HIMS follow?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":562441876075664,"tweetId":"562441876075664","gmtCreate":1778344815855,"gmtModify":1778344819187,"author":{"id":3579620689202711,"idStr":"3579620689202711","authorId":3579620689202711,"authorIdStr":"3579620689202711","name":"shanechang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"82ffa69a97264fba9002044f4f5f535b-1","templateUuid":"82ffa69a97264fba9002044f4f5f535b","name":"Tiger Think Tank","description":"Tiger Think Tank","bigImgUrl":"https://community-static.tradeup.com/news/193f8255673f42bdc610097b2074ec3e","smallImgUrl":"https://community-static.tradeup.com/news/06af124f59f026a383d35b268362424f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.20","individualDisplayEnabled":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"82ffa69a97264fba9002044f4f5f535b-1","name":"Tiger Think Tank","description":"Tiger Think Tank","smallImgUrl":"https://community-static.tradeup.com/news/06af124f59f026a383d35b268362424f","bigImgUrl":"https://community-static.tradeup.com/news/193f8255673f42bdc610097b2074ec3e","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","name":"Real Trader","description":"Completed a transaction","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","name":" Tiger Idol","description":"Join the tiger community for 1500 days","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":1,"starInvestorFlag":false},"themes":[{"themeId":"ab38a1599f2b4becb1fee7b45df87b9b","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"Healthcare Recovery: Can Hims Earnings Keep Pace With LLY and NVO?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":ab38a1599f2b4becb1fee7b45df87b9b}&rnconfig={\"headerBarHidden\": true}","description":"Hims & Hers is set to report Q1 earnings, with focus on GLP-1 compounded semaglutide's quarterly revenue contribution and user growth, alongside the latest FDA regulatory developments on compounded drugs. Analyst sentiment is sharply divided — bulls argue HIMS has hedged GLP-1 compliance risk through product line diversification, while bears warn an outright FDA ban on compounded versions could trigger a steep revenue cliff. LLY delivered a strong earnings beat this season, surging 10% on the day. Can HIMS follow?","image":"https://community-static.tradeup.com/news/fd159dbf87cadcf6c3f1da47474df2e9"}],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>The healthcare sector is having a massive recovery, and everyone is asking: can Hims &amp; Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\\(LLY / \\)NVO): They own the \"gold standard\" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from \"knock-offs\" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit</p></body></html>","htmlText":"<html><head></head><body><p>The healthcare sector is having a massive recovery, and everyone is asking: can Hims &amp; Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\\(LLY / \\)NVO): They own the \"gold standard\" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from \"knock-offs\" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit</p></body></html>","text":"The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\\(LLY / \\)NVO): They own the \"gold standard\" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from \"knock-offs\" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/562441876075664","repostId":0,"isVote":1,"tweetType":1,"viewCount":337,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVO"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":636,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/562441876075664"}